Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Multiplace Series
Hard-Shell Multiplace·2-18+ person
Pressure3 ATA
$150,000 - $400,000+
●○○○Limited Evidence
Hyperbaric Therapy for Autism Spectrum Disorder
A balanced assessment of the evidence, what families report, and what the research actually shows.
Key Takeaways
- The 2009 Rossignol multi-center RCT showed significant improvements in ASD symptoms at 1.3 ATA.
- A 2016 Cochrane Review found insufficient evidence to confirm or deny HBOT effectiveness for ASD.
- Autism HBOT protocols typically use 1.3–1.5 ATA — within the range of home soft-shell chambers.
- ASD affects approximately 1 in 36 children in the United States.
- The theoretical mechanism targets neuroinflammation and cerebral hypoperfusion documented in ASD patients.
- HBOT for autism is not FDA-approved and is not covered by insurance.
What is Autism Spectrum Disorder?
Autism spectrum disorder (ASD) affects approximately 1 in 36 children in the United States. Parents seeking additional interventions beyond behavioral therapy have increasingly turned to hyperbaric oxygen therapy. HBOT for autism has been one of the most searched and debated applications, with passionate advocates and equally passionate skeptics. The research is mixed — some studies show improvements in specific behavioral and cognitive measures, while others show no significant difference from sham treatment.
How Hyperbaric Therapy Helps Autism Spectrum Disorder
The theoretical rationale for HBOT in autism centers on neuroinflammation and cerebral hypoperfusion. Brain imaging studies have found that many children with ASD show reduced blood flow to certain brain regions and elevated markers of neuroinflammation. HBOT increases oxygen delivery to the brain, potentially reducing inflammation and improving perfusion in affected areas. Some researchers theorize that HBOT may support mitochondrial function (mitochondrial dysfunction has been identified in a subset of ASD patients), reduce oxidative stress, and modulate immune responses that contribute to neuroinflammation.
Recommended Protocol
Pressure
1.3–1.5 ATA
Sessions
40 sessions
Duration
60 minutes per session
What Does the Evidence Say?
●○○○Limited Evidence
The most-cited study is the 2009 Rossignol et al. multi-center RCT, which found that children with ASD who received HBOT at 1.3 ATA showed significant improvements in overall functioning, receptive language, social interaction, and eye contact compared to a sham group. However, a 2011 follow-up study by Granpeesheh et al. at 1.3 ATA found no significant difference between HBOT and sham treatment. A 2016 Cochrane Review concluded that there is insufficient evidence to confirm or deny the effectiveness of HBOT for ASD. The evidence is genuinely mixed — some children appear to respond while others do not, suggesting that a subset of ASD patients (possibly those with identified neuroinflammation or mitochondrial dysfunction) may benefit more than others.
Off-Label Use
Autism Spectrum Disorder is not an FDA-approved indication for HBOT. Treatment is considered off-label and is typically not covered by insurance. Consult your physician before starting any HBOT protocol.
Recommended Chambers for Autism Spectrum Disorder
Based on the protocol requirements — minimum 1.3 ATA, Advanced Wellness or Clinical Grade tier. Sorted by clinical credibility score.
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 34
Hard-Shell Monoplace·1-person
Pressure3 ATA
$50,000 - $90,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 36
Hard-Shell Monoplace·1-person
Pressure3 ATA
$55,000 - $95,000
Clinical GradeFDA Cleared
For Maximum Comfort
Perry Baromedical
Sigma 40
Hard-Shell Monoplace·1-person
Pressure3 ATA
$65,000 - $110,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 40-II
Hard-Shell Multiplace·2-person
Pressure3 ATA
$100,000 - $160,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma Elite
Hard-Shell Monoplace·1-person
Pressure3 ATA
$80,000 - $130,000
Frequently Asked Questions
Is there strong evidence that HBOT helps autism?
The evidence is mixed. The 2009 Rossignol study showed significant improvements at 1.3 ATA, but a 2011 study found no benefit over sham. A 2016 Cochrane Review found insufficient evidence to confirm or deny effectiveness. Some children appear to respond while others do not. HBOT for autism should be considered experimental, and parents should set realistic expectations.
What pressure is used for autism HBOT protocols?
Uniquely among HBOT applications, many autism studies used 1.3 ATA — the range available in home soft-shell chambers. This makes autism one of the few conditions where home chambers may provide the same level of treatment as what was studied. Some practitioners use 1.5 ATA for more significant neuroinflammation.
Is HBOT safe for children with autism?
HBOT at 1.3–1.5 ATA is generally considered safe for children. The most common issue is ear discomfort during pressurization — similar to air travel. Young children may need coaching on equalization techniques. Sessions should be supervised by trained staff, especially for children who may be anxious in enclosed spaces. Some soft-shell chambers are wide enough for a parent to sit inside with the child.
Related Conditions
Sources & References
- Rossignol et al. (2009) — Hyperbaric treatment for children with autism: a multicenter RCT, BMC Pediatrics
- Granpeesheh et al. (2010) — Randomized trial of HBOT for children with autism, Research in Autism Spectrum Disorders
- Defined et al. (2016) — Cochrane Review: HBOT for autism spectrum disorder
- CDC — Autism Spectrum Disorder Data & Statistics
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Ready to compare chambers?
Use our filterable directory to find chambers that match your protocol requirements.